Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
This month ELF attended the Open Info Day Horizon 2020 “Health, demographic change and wellbeing” in Brussels.
The area of health and research benefits from funding through a series of programmes created by the European Commission (EC). These include the Horizon 2020 programme and the Innovative Medicines Initiative.
For 2017, one of the top priorities in research is personalised medicine. Pioneering projects on new therapies on and profiling of rare conditions will also be funded. Areas of e/m-health and coaching tools will also be included, specifically in topics connected to healthy ageing. The EC is keen on maintaining a patient-centred approach, working towards patient empowerment.
During the conference, Ruxandra Draghia-Akli, Director of the Health Directorate at the Directorate-General of Research and Innovation at the EC, covered some key points including that:
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79